Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMajem Tarruella, Margarita
dc.contributor.authorManzano, Jose Luis
dc.contributor.authorMarquez‑Rodas, I.
dc.contributor.authorMujika, K.
dc.contributor.authorMuñoz Couselo, Eva
dc.contributor.authorPérez‑Ruiz, E.
dc.date.accessioned2022-01-25T11:27:29Z
dc.date.available2022-01-25T11:27:29Z
dc.date.issued2021-05
dc.identifier.citationMajem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, et al. SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 2021 May;23:948–960.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/6887
dc.descriptionAdjuvant treatment; Melanoma; Staging
dc.description.abstractMelanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;23
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMelanoma - Tractament
dc.subjectAdjuvants immunològics - Ús terapèutic
dc.subjectMedicina clínica - Presa de decisions
dc.subject.meshMelanoma
dc.subject.mesh/therapy
dc.subject.meshImmunotherapy
dc.subject.meshPractice Guideline
dc.titleSEOM clinical guideline for the management of cutaneous melanoma (2020)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-020-02539-9
dc.subject.decsmelanoma
dc.subject.decs/terapia
dc.subject.decsinmunoterapia
dc.subject.decsguía de práctica clínica
dc.relation.publishversionhttps://doi.org/10.1007/s12094-020-02539-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. [Manzano JL] Department of Medical Oncology, H. Germans Trias i Pujol, Catalan Institute of Oncology, ICO-Badalona, Badalona, Spain. [Marquez-Rodas I] Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón and CIBERONC, Madrid, Spain. [Mujika K] Department of Medical Oncology, UGC de Oncología de Gipuzkoa, OSI Donostialdea-Onkologikoa, Guipúzcoa, Spain. [Muñoz-Couselo E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pérez-Ruiz E] Department of Medical Oncology, Hospital Costa del Sol and UGC Oncol, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional Virgen Victoria, Málaga, Spain
dc.identifier.pmid33651321
dc.identifier.wos000624437100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record